Trial Profile
The effects of weekly administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients with normal IGF-I [insulin-like growth factor-I] concentrations during long-term treatment with long-acting somatostatin analogs
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- 09 Apr 2008 New trial record.